StemCells, Inc. Announces Webcast to Discuss Third Quarter 2012 Financial Results and Business Update

StemCells, Inc. Announces Webcast to Discuss Third Quarter 2012 Financial
Results and Business Update

NEWARK, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM), a leading stem cell company developing and commercializing
novel cell-based therapeutics and tools for use in stem cell-based research
and drug discovery, announced today that it will release financial results for
the third quarter ended September 30, 2012 after the market close on Thursday,
November 8. In connection with this announcement, StemCells will host a
conference call and webcast to discuss its results and an update on its
business at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day.

Interested parties are invited to listen to the call over the Internet by
accessing the Investors section of the Company's website at
www.stemcellsinc.com. Webcast participants should allot extra time before the
webcast begins to register and, if necessary, download and install audio
software.

Event:  Q3 2012 Financial Results Conference Call / Webcast
         
Date:    Thursday, November 8, 2012
         
Time:     1:30 PM PT (4:30 PM ET)
         
Live      http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome
webcast:

An archived version of the webcast will also be available for replay on the
Company's website beginning approximately two hours following the conclusion
of the live call and continuing for a period of 30 days.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells.The Company is also conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland and recently
reported positive interim data for the first patient cohort.The Company is
also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD), and is pursuing preclinical studies in Alzheimer's
disease.StemCells also markets stem cell research products, including media
and reagents, under the SC Proven® brand.Further information about StemCells
is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of its HuCNS-SC cells; the Company's ability to commercialize drug
discovery and drug development tools; and the future business operations of
the Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. Such statements reflect management's current views and are
based on certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company
is subject, including those described under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2011
and in its subsequent reports on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
        
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
 
Press spacebar to pause and continue. Press esc to stop.